{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-10-13T09:28:49.381376+00:00","company":{"ticker":"VSBC","cik":1697884,"company_name":"VITASPRING BIOMEDICAL CO. LTD."},"pagination":{"limit":100,"returned":10,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","counterparties":{},"facts":[{"fact_type":"executive_change","fact_key":"24f00f37d2","cik":1697884,"ticker":"VSBC","company_name":"VITASPRING BIOMEDICAL CO. LTD.","filed_at":"2026-09-10T17:22:10+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2026-09-07","interim":false,"role":"Chairman of the Board","role_category":"chair","successor_name":null,"successor_named":false},"claim":"Shao-Hsiang Shih was appointed as Chairman of the Board at VITASPRING BIOMEDICAL CO. LTD..","evidence_excerpt":"Effective at 11:57 p.m. Pacific Time on September 7, 2026, Mr. Shih was appointed Chairman of the Board, to serve at the pleasure of the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001640334-26-001485","anchor_url":"https://secwatch.observer/filing/0001640334-26-001485#claim-24f00f37d2","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1697884/000164033426001485/0001640334-26-001485-index.htm"},{"fact_type":"executive_change","fact_key":"efc485f4ae","cik":1697884,"ticker":"VSBC","company_name":"VITASPRING BIOMEDICAL CO. LTD.","filed_at":"2026-09-10T17:22:10+00:00","payload":{"action":"elected","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2026-09-07","interim":false,"role":"Director","role_category":"director","successor_name":null,"successor_named":false},"claim":"Shao-Hsiang Shih was elected as Director at VITASPRING BIOMEDICAL CO. LTD..","evidence_excerpt":"Effective at 11:56 p.m. Pacific Time on September 7, 2026, Ssu-Chuan Lai, as the sole director then in office, elected Shao-Hsiang Shih to serve as a director of the Company, to hold office until the next annual meeting of stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001640334-26-001485","anchor_url":"https://secwatch.observer/filing/0001640334-26-001485#claim-efc485f4ae","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1697884/000164033426001485/0001640334-26-001485-index.htm"},{"fact_type":"executive_change","fact_key":"8021a2d69c","cik":1697884,"ticker":"VSBC","company_name":"VITASPRING BIOMEDICAL CO. LTD.","filed_at":"2026-09-10T17:22:10+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2026-09-07","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Jing-Zhou Chen was appointed as Chief Executive Officer at VITASPRING BIOMEDICAL CO. LTD..","evidence_excerpt":"Effective at 11:57 p.m. Pacific Time on September 7, 2026, Dr. Ssu-Chuan Lai, as the sole director then in office, appointed Jing-Zhou Chen as the Company’s Chief Executive Officer, President, Chief Financial Officer, and Secretary, to serve at the pleasure of the Board and until his successor is duly appointed and qualified, or until his earlier death, resignation or removal.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001640334-26-001485","anchor_url":"https://secwatch.observer/filing/0001640334-26-001485#claim-8021a2d69c","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1697884/000164033426001485/0001640334-26-001485-index.htm"},{"fact_type":"executive_change","fact_key":"67cac393c1","cik":1697884,"ticker":"VSBC","company_name":"VITASPRING BIOMEDICAL CO. LTD.","filed_at":"2026-09-10T17:22:10+00:00","payload":{"action":"resigned","action_category":"departure","departure_tone":"routine","effective_date":"2026-09-07","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":"Jing-Zhou Chen","successor_named":true},"claim":"Ssu-Chuan Lai resigned as Chief Executive Officer at VITASPRING BIOMEDICAL CO. LTD..","evidence_excerpt":"Effective at 11:58 p.m. Pacific Time on September 7, 2026, immediately following the election of her successor as a director and the appointment of her successor officers as described in Items 5.02(c) and (d) below, Dr. Ssu-Chuan Lai resigned from her positions as Chairperson of the Board, Chief Executive Officer, President, Chief Financial Officer, and Secretary of the Company, and as a member of the Board.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001640334-26-001485","anchor_url":"https://secwatch.observer/filing/0001640334-26-001485#claim-67cac393c1","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1697884/000164033426001485/0001640334-26-001485-index.htm"},{"fact_type":"auditor_change","fact_key":"72e62a926e22f46e6b56e9e08c464e3f505b4b04","cik":1697884,"ticker":"VSBC","company_name":"VITASPRING BIOMEDICAL CO. LTD.","filed_at":"2025-08-25T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"JP Centurion & Partners PLT","disagreement_text":null,"effective_date":"2025-08-19","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"VITASPRING BIOMEDICAL CO. LTD. engaged JP Centurion & Partners PLT as its auditor.","evidence_excerpt":"On August 19, 2025, the Board of Directors of VitaSpring Biomedical Co., Ltd. (the “Company”) approved the engagement of JP Centurion & Partners PLT (“JP Centurion”) as the Company’s independent registered public accounting firm, effective as of such date.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001683168-25-006448","anchor_url":"https://secwatch.observer/filing/0001683168-25-006448#claim-72e62a926e22f46e6b56e9e08c464e3f505b4b04","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1697884/000168316825006448/0001683168-25-006448-index.htm"},{"fact_type":"auditor_change","fact_key":"4c8490fc79a0bc7511d03bc0e9b79c38d688d5f8","cik":1697884,"ticker":"VSBC","company_name":"VITASPRING BIOMEDICAL CO. LTD.","filed_at":"2025-08-11T23:59:59+00:00","payload":{"action":"resignation","auditor_name":"TAAD LLP","disagreement_text":null,"effective_date":"2025-08-05","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"TAAD LLP resigned as auditor of VITASPRING BIOMEDICAL CO. LTD..","evidence_excerpt":"On August 5, 2025, TAAD LLP (“TAAD”) resigned as our independent registered public accounting firm, effective immediately.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001683168-25-005896","anchor_url":"https://secwatch.observer/filing/0001683168-25-005896#claim-4c8490fc79a0bc7511d03bc0e9b79c38d688d5f8","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1697884/000168316825005896/0001683168-25-005896-index.htm"},{"fact_type":"auditor_change","fact_key":"f2429673da390666b407aa8163508e133956ecc5","cik":1697884,"ticker":"VSBC","company_name":"VITASPRING BIOMEDICAL CO. LTD.","filed_at":"2023-01-27T23:59:59+00:00","payload":{"action":"engagement","auditor_name":"TAAD LLP","disagreement_text":null,"effective_date":"2023-01-24","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":null},"claim":"VITASPRING BIOMEDICAL CO. LTD. engaged TAAD LLP as its auditor.","evidence_excerpt":"On January 24, 2023, our board of directors approved the engagement of TAAD LLP (\"TAAD\"), as the Company's new independent registered public accounting firm.","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001697884-23-000002","anchor_url":"https://secwatch.observer/filing/0001697884-23-000002#claim-f2429673da390666b407aa8163508e133956ecc5","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1697884/000169788423000002/0001697884-23-000002-index.htm"},{"fact_type":"auditor_change","fact_key":"91d7dc9ebb1f869e9ab414bb65257f4462e387e3","cik":1697884,"ticker":"VSBC","company_name":"VITASPRING BIOMEDICAL CO. LTD.","filed_at":"2023-01-27T23:59:59+00:00","payload":{"action":"resignation","auditor_name":"Kho & Patel, Certified Public Accountants","disagreement_text":null,"effective_date":"2023-01-17","item_codes_triggered":["4.01"],"non_reliance_signal":"none","successor_auditor_name":"TAAD LLP"},"claim":"Kho & Patel, Certified Public Accountants resigned as auditor of VITASPRING BIOMEDICAL CO. LTD..","evidence_excerpt":"On January 17, 2023, Kho & Patel, Certified Public Accountants, (\"Kho\"), resigned as the independent registered public accounting firm of Vitaspring Biomedical Co. Ltd. (the \"Company\").","confidence":0.9,"filing_url":"https://secwatch.observer/filing/0001697884-23-000002","anchor_url":"https://secwatch.observer/filing/0001697884-23-000002#claim-91d7dc9ebb1f869e9ab414bb65257f4462e387e3","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1697884/000169788423000002/0001697884-23-000002-index.htm"},{"fact_type":"executive_change","fact_key":"5b2f961f69","cik":1697884,"ticker":"VSBC","company_name":"VITASPRING BIOMEDICAL CO. LTD.","filed_at":"2021-08-11T23:59:59+00:00","payload":{"action":"appointed","action_category":"appointment","departure_tone":"not_applicable","effective_date":"2020-08-07","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":null,"successor_named":false},"claim":"Kao Cheng-Hsiang was appointed as Chief Executive Officer at VITASPRING BIOMEDICAL CO. LTD..","evidence_excerpt":"current secretary of the Company, Kao Cheng-Hsiang, was appointed CEO and retains his position as Secretary.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001697884-21-000011","anchor_url":"https://secwatch.observer/filing/0001697884-21-000011#claim-5b2f961f69","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1697884/000169788421000011/0001697884-21-000011-index.htm"},{"fact_type":"executive_change","fact_key":"bda774e922","cik":1697884,"ticker":"VSBC","company_name":"VITASPRING BIOMEDICAL CO. LTD.","filed_at":"2021-08-11T23:59:59+00:00","payload":{"action":"resigned","action_category":"role_change","departure_tone":"routine","effective_date":"2020-08-07","interim":false,"role":"Chief Executive Officer","role_category":"ceo","successor_name":"Kao Cheng-Hsiang","successor_named":true},"claim":"Chu Pao-Chi resigned as Chief Executive Officer at VITASPRING BIOMEDICAL CO. LTD..","evidence_excerpt":"Effective August 7, 2020, Chu Pao-Chi Chairman of the Board of Directors, and Chief Executive Officer of the Company, resigned his position as CEO","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001697884-21-000011","anchor_url":"https://secwatch.observer/filing/0001697884-21-000011#claim-bda774e922","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/1697884/000169788421000011/0001697884-21-000011-index.htm"}]}